Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs CESAMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
1-2 mg orally twice daily; maximum 6 mg/day.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal elimination half-life is approximately 35 hours (range 25–50 hours) in adults. Due to prolonged half-life and active metabolites, steady-state may take 5–7 days; accumulation occurs with repeated dosing.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Hepatic, primarily via CYP3A4 and CYP2C9; undergoes first-pass metabolism; multiple metabolites including active 11-hydroxy-nabilone
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Primarily hepatic metabolism with biliary excretion. ~65% eliminated in feces as metabolites, ~20% in urine. Less than 1% excreted unchanged.
10-25% bound to albumin at therapeutic concentrations.
90–95% bound to plasma proteins, primarily albumin.
0.8-1.0 L/kg. Indicates distribution into total body water.
Approximately 2.5–5.5 L/kg, indicating extensive tissue distribution.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No specific dosage adjustment recommended based on GFR; use with caution in severe renal impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Start at 1 mg once daily; titrate slowly due to increased sensitivity to adverse effects.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
None
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Central nervous system depression (drowsiness, dizziness, ataxia),Psychiatric effects (euphoria, dysphoria, paranoia, hallucinations),Cognitive and motor impairment (do not drive or operate machinery),Risk of dependence and withdrawal syndrome,Use with caution in patients with history of psychiatric disorders,May increase heart rate and blood pressure
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Hypersensitivity to nabilone or any cannabinoid,History of seizure disorder,Breastfeeding (excreted in milk)
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Take with food or milk to reduce gastrointestinal upset; avoid grapefruit juice as it may alter drug metabolism.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may increase risk of congenital malformations. Second and third trimester exposure may affect fetal growth and neurobehavioral development. Potential risks include low birth weight, preterm birth, and neonatal withdrawal symptoms.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Nabilone is excreted into breast milk; a specific M/P ratio is not reported. Due to the high lipid solubility and long half-life, significant infant exposure is expected. Breastfeeding is contraindicated due to potential adverse effects on infant neurodevelopment and cannabinoid receptor activation.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced hepatic metabolism) may reduce nabilone serum concentrations, potentially requiring dose adjustments. However, due to lack of safety data, use during pregnancy is not recommended. If deemed essential, the lowest effective dose should be used, and close monitoring for efficacy and toxicity is advised.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Titrate slowly to reduce risk of syncope and orthostatic hypotension; monitor for dizziness and sedation; may cause euphoria or dysphoria; use with caution in patients with history of psychiatric disorders; taper to discontinue.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Avoid driving or operating machinery until you know how this drug affects you.,Get up slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol and other sedatives while taking this medication.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs CESAMET, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. CESAMET is a Antiemetic (cannabinoid) that works by Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and CESAMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of CESAMET is: 1-2 mg orally twice daily; maximum 6 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and CESAMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. CESAMET is classified as Category C. Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommende. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.